Bushu Pharma Wins Frost & Sullivan’s 2024 APAC Customer Value Leadership Award

• Bushu Pharma received the 2024 APAC Customer Value Leadership Award from Frost & Sullivan for its excellence in contract development and manufacturing services.

• The company’s innovative technologies, sustainability efforts, and customer-focused approach have solidified its leadership in the CDMO industry.

Bushu Pharma has been honoured with Frost & Sullivan’s 2024 APAC Customer Value Leadership Award for its outstanding contributions to the contract development and manufacturing organization (CDMO) industry. The Japan-based pharmaceutical and medical device manufacturer earned recognition for its comprehensive service offerings, global reach, and commitment to sustainability.

Bushu Pharma provides end-to-end services, including development, manufacturing, packaging, regulatory compliance, and supply chain management, catering to the needs of over 95 global clients. Its capabilities span from small molecule drugs to complex biologics, including sterile and high-potency products. With regulatory approvals from agencies such as the FDA and EMA, the company ensures the consistent delivery of high-quality products to 56 countries.

Rubini Kamal, a best practices research analyst at Frost & Sullivan, highlighted the company’s strengths, stating, “Bushu Pharma’s strategic focus on forging partnerships addresses critical challenges with drug availability and market entry, enhancing its offerings while bridging market gaps and improving healthcare accessibility.”

Beyond operational excellence, Bushu Pharma continues to lead in sustainability. It employs renewable energy, reduces packaging waste, and monitors wastewater quality. Cutting-edge innovations, such as automated guided forklifts and collaborative robots, further improve efficiency and maintain quality standards.

Through initiatives like its “GATEWAY to ASIA” services, Bushu Pharma simplifies market entry for international clients, reduces logistics costs, and minimises carbon emissions. These efforts, combined with its Bushu Continuity Plan for disaster resilience, position the company as a trusted partner in the global pharmaceutical supply chain.